Total Payments
$405,357
2024 Payments
$132,336
Companies
35
Transactions
546
Medicare Patients
785
Medicare Billing
$145,048
Payment Breakdown by Category
Consulting$176,234 (43.5%)
Other$162,386 (40.1%)
Travel$41,001 (10.1%)
Food & Beverage$13,659 (3.4%)
Research$11,969 (3.0%)
Education$108.22 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $176,234 | 57 | 43.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $86,321 | 35 | 21.3% |
| Honoraria | $73,348 | 27 | 18.1% |
| Travel and Lodging | $41,001 | 151 | 10.1% |
| Food and Beverage | $13,659 | 257 | 3.4% |
| Unspecified | $11,969 | 12 | 3.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,717 | 2 | 0.7% |
| Education | $108.22 | 5 | 0.0% |
Payments by Type
General
$393,388
534 transactions
Research
$11,969
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $148,757 | 181 | $0 (2024) |
| Blueprint Medicines Corporation | $73,165 | 90 | $0 (2024) |
| ABBVIE INC. | $34,835 | 64 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $16,970 | 13 | $0 (2024) |
| Merck Sharp & Dohme LLC | $16,155 | 9 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $13,936 | 32 | $0 (2020) |
| F. Hoffmann-La Roche AG | $10,682 | 8 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $9,843 | 21 | $0 (2022) |
| SERVIER PHARMACEUTICALS LLC | $9,509 | 15 | $0 (2024) |
| CTI BioPharma Corp. | $8,692 | 11 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $132,336 | 137 | Incyte Corporation ($43,790) |
| 2023 | $75,755 | 122 | Blueprint Medicines Corporation ($27,078) |
| 2022 | $83,211 | 90 | Incyte Corporation ($24,553) |
| 2021 | $18,189 | 27 | Incyte Corporation ($8,460) |
| 2020 | $31,971 | 33 | Incyte Corporation ($20,128) |
| 2019 | $45,888 | 87 | Incyte Corporation ($21,607) |
| 2018 | $17,798 | 48 | Daiichi Sankyo Inc. ($6,211) |
| 2017 | $209.44 | 2 | Gilead Sciences Inc ($109.44) |
All Payment Transactions
546 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $58.23 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/07/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $162.09 | General |
| Category: Oncology | ||||||
| 12/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $59.61 | General |
| 12/05/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $46.53 | General |
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $5,236.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,232.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Travel and Lodging | Cash or cash equivalent | $121.14 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $120.79 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/15/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Consulting Fee | Cash or cash equivalent | $3,400.00 | General |
| Category: Oncology | ||||||
| 11/15/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | Cash or cash equivalent | $698.95 | General |
| Category: Oncology | ||||||
| 11/15/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | Cash or cash equivalent | $383.13 | General |
| Category: Oncology | ||||||
| 11/15/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | Cash or cash equivalent | $77.17 | General |
| Category: Oncology | ||||||
| 11/15/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | Cash or cash equivalent | $71.21 | General |
| Category: Oncology | ||||||
| 11/15/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | Cash or cash equivalent | $36.17 | General |
| Category: Oncology | ||||||
| 11/14/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 11/13/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,232.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/09/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Travel and Lodging | In-kind items and services | $269.63 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Travel and Lodging | In-kind items and services | $432.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/08/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Travel and Lodging | In-kind items and services | $371.96 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/08/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Travel and Lodging | In-kind items and services | $80.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/08/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $64.75 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Travel and Lodging | In-kind items and services | $56.25 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/08/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $46.45 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Pre- versus Post-VIALE-A Experience of Venetoclax in Combination with Hypomethylating Agents in Patients with Newly Diagnosed AML from a Predominantly US Community Setting | F. Hoffmann-La Roche AG | $3,343 | 1 |
| VENETOCLAX AND HYPOMETHYLATING AGENTS AS FIRST-LINE TREATMENT IN NEWLY DIAGNOSED PATIENTS WITH AML IN A PREDOMINATELY COMMUNITY SETTING IN THE US | F. Hoffmann-La Roche AG | $2,995 | 1 |
| Treatment Effectiveness of Venetoclax in Combination with Hypomethylating Agents in Patient Subgroups with Acute Myeloid Leukemia: Experience from Routine Clinical Practices in the United States | F. Hoffmann-La Roche AG | $1,780 | 2 |
| The Cytogenetic and Molecular Testing Landscape in Patients with Newly Diagnosed Acute Myeloid Leukemia in Routine Clinical Practices in the United States | F. Hoffmann-La Roche AG | $1,441 | 2 |
| AMG 673 Ph1/2 Multiple hematologic indications | Amgen Inc. | $853.59 | 1 |
| Treatment Outcomes of Stem Cell Transplant in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents: Experience from Routine Clinical Practices in the US | F. Hoffmann-La Roche AG | $626.44 | 1 |
| REAL WORLD TREATMENT PATTERNS AND OUTCOMES OF VENETOCLAX VEN AND HYPOMETHYLATING AGENTS HMA IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA AML IN THE UNITED STATES | F. Hoffmann-La Roche AG | $495.09 | 1 |
| PF06647263 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF | GlaxoSmithKline, LLC. | $103.92 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 208 | 497 | $140,189 | $40,013 |
| 2022 | 6 | 191 | 423 | $119,722 | $33,604 |
| 2021 | 5 | 191 | 436 | $122,436 | $34,045 |
| 2020 | 5 | 195 | 548 | $140,802 | $37,386 |
Total Patients
785
Total Services
1,904
Medicare Billing
$145,048
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 39 | 246 | $73,062 | $21,774 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 64 | 113 | $27,798 | $7,782 | 28.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 23 | 33 | $11,517 | $3,426 | 29.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 27 | 27 | $13,743 | $3,111 | 22.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 18 | 24 | $4,248 | $1,415 | 33.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 23 | $4,830 | $1,365 | 28.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 26 | 31 | $4,991 | $1,141 | 22.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 203 | $60,291 | $16,164 | 26.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 65 | 111 | $27,306 | $8,018 | 29.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 19 | 32 | $11,168 | $3,508 | 31.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 24 | 24 | $12,216 | $3,400 | 27.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 34 | 40 | $6,440 | $1,788 | 27.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 13 | 13 | $2,301 | $724.91 | 31.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 44 | 222 | $65,934 | $17,991 | 27.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 66 | 116 | $28,536 | $8,524 | 29.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 28 | 28 | $14,252 | $3,614 | 25.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 40 | 57 | $9,177 | $2,410 | 26.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 13 | 13 | $4,537 | $1,505 | 33.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 57 | 340 | $100,980 | $27,888 | 27.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 85 | 153 | $24,633 | $5,480 | 22.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 16 | 16 | $8,144 | $2,027 | 24.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 22 | 24 | $5,904 | $1,490 | 25.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 15 | 15 | $1,141 | $501.48 | 44.0% |
About Dr. Pankit Vachhani, MD
Dr. Pankit Vachhani, MD is a Hematology & Oncology healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2012. The National Provider Identifier (NPI) number assigned to this provider is 1982968764.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Pankit Vachhani, MD has received a total of $405,357 in payments from pharmaceutical and medical device companies, with $132,336 received in 2024. These payments were reported across 546 transactions from 35 companies. The most common payment nature is "Consulting Fee" ($176,234).
As a Medicare-enrolled provider, Vachhani has provided services to 785 Medicare beneficiaries, totaling 1,904 services with total Medicare billing of $145,048. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Birmingham, AL
- Active Since 06/27/2012
- Last Updated 06/28/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1982968764
Products in Payments
- JAKAFI (Drug) $118,422
- AYVAKIT (Drug) $29,830
- VENCLEXTA (Drug) $20,471
- XPOVIO (Drug) $16,970
- TIBSOVO (Drug) $14,485
- VENCLEXTA (Biological) $11,695
- VYXEOS (Drug) $9,715
- Vonjo (Drug) $8,692
- KEYTRUDA (Biological) $8,685
- Venclexta (Biological) $7,205
- VONJO (Drug) $5,685
- Tibsovo (Drug) $4,667
- Venclexta (Drug) $4,226
- ELZONRIS (Drug) $4,078
- XOSPATA (Drug) $3,572
- BESPONSA (Biological) $3,510
- BESREMI (Drug) $3,500
- ICLUSIG (Drug) $3,300
- OJJAARA (Drug) $2,015
- ABL002 (Drug) $1,980
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Birmingham
Dr. Khaleel Ashraf, M.d, M.D
Hematology & Oncology — Payments: $628,093
Hematology & Oncology $628,093
Amitkumar Mehta
Hematology & Oncology — Payments: $581,179
Hematology & Oncology $581,179
Luciano Costa
Hematology & Oncology — Payments: $447,833
Hematology & Oncology $447,833
Dr. Michael Birrer, M.d. Ph.d, M.D. PH.D
Hematology & Oncology — Payments: $432,657
Hematology & Oncology $432,657
Robert Conry, Md, MD
Hematology & Oncology — Payments: $219,082
Hematology & Oncology $219,082
Dr. Mayur Narkhede, M.d, M.D
Hematology & Oncology — Payments: $205,834
Hematology & Oncology $205,834